Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Armand, Philippe, Janssens, Ann, Gritti, Giuseppe, Radford, John, Timmerman, John, Pinto, Antonio, Mercadal Vilchez, Santiago, Johnson, Peter, Cunningham, David, Leonard, John P., Rodig, Scott J., Martín-Regueira, Patricia, Sumbul, Anne, Samakoglu, Selda, Tang, Hao, Ansell, Stephen M.
Published in Blood (04.02.2021)
Published in Blood (04.02.2021)
Get full text
Journal Article
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE
Shah, Neil P., García‐Gutiérrez, Valentín, Jiménez‐Velasco, Antonio, Larson, Sarah M., Saussele, Susanne, Rea, Delphine, Mahon, François‐Xavier, Levy, Moshe Yair, Gómez‐Casares, María Teresa, Mauro, Michael J., Sy, Oumar, Martin‐Regueira, Patricia, Lipton, Jeffrey H.
Published in British journal of haematology (01.09.2023)
Published in British journal of haematology (01.09.2023)
Get full text
Journal Article
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
DiNardo, Courtney D, Schuh, Andre C, Stein, Eytan M, Montesinos, Pau, Wei, Andrew H, de Botton, Stéphane, Zeidan, Amer M, Fathi, Amir T, Kantarjian, Hagop M, Bennett, John M, Frattini, Mark G, Martin-Regueira, Patricia, Lersch, Frederik, Gong, Jing, Hasan, Maroof, Vyas, Paresh, Döhner, Hartmut
Published in The lancet oncology (01.11.2021)
Published in The lancet oncology (01.11.2021)
Get full text
Journal Article
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, DiNardo, Courtney D.
Published in Blood (12.01.2023)
Published in Blood (12.01.2023)
Get full text
Journal Article
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Shah, Neil P., García-Gutiérrez, Valentín, Jiménez-Velasco, Antonio, Larson, Sarah, Saussele, Susanne, Rea, Delphine, Mahon, François-Xavier, Levy, Moshe Yair, Gómez-Casares, María Teresa, Pane, Fabrizio, Nicolini, Franck-Emmanuel, Mauro, Michael J., Sy, Oumar, Martin-Regueira, Patricia, Lipton, Jeffrey H.
Published in Leukemia & lymphoma (23.02.2020)
Published in Leukemia & lymphoma (23.02.2020)
Get full text
Journal Article
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN
Cortes, Jorge E, Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael, Martin-Regueira, Patricia, Sy, Oumar, Saglio, Giuseppe
Published in Haematologica (Roma) (01.10.2024)
Published in Haematologica (Roma) (01.10.2024)
Get full text
Journal Article
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael, Martin-Regueira, Patricia, Sy, Oumar, Gurnani, Renuka, Saglio, Giuseppe
Published in Leukemia (01.08.2020)
Published in Leukemia (01.08.2020)
Get full text
Journal Article
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN
Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Published in Haematologica (Roma) (01.05.2024)
Published in Haematologica (Roma) (01.05.2024)
Get full text
Journal Article
Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
Gupta, Vikas, Yacoub, Abdulraheem, Verstovsek, Srdan, Mesa, Ruben, Harrison, Claire, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Deeg, H. Joachim, Fazal, Salman, Foltz, Lynda, Mattison, Ryan J., Miller, Carole B., Parameswaran, Vinod, Martin-Regueira, Patricia, Hernandez, Christopher, Wang, Jia, Talpaz, Moshe
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael R., Martin-Regueira, Patricia, Sy, Oumar, Saglio, Giuseppe
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
Dinardo, Courtney Denton, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Zeidan, Amer Methqal, Chen, Clara, Lord-Bessen, Jennifer, Yu, Peiwen, Shi, Ling, Guo, Shien, Bluemmert, Iryna, Yu, Xin, Hasan, Maroof, Martin Regueira, Patricia, De Botton, Stéphane
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
DiNardo, Courtney D., Dohner, Hartmut, Zeidan, Amer M., Schuh, Andre C., Vyas, Paresh, Stein, Eytan M., Wei, Andrew H., de Botton, Stephane, Chen, Clara, Lord-Bessen, Jennifer, Martin-Regueira, Patricia, Lersch, Frederik, Gong, Jing, Guo, Shien, Shi, Ling, Montesinos, Pau
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)
DiNardo, Courtney D., Borthakur, Gautam, Ball, Brian, Erba, Harry P., Mawad, Raya, Kremyanskaya, Marina, Blachly, James S., Carraway, Hetty E., Youn, Ahrim, Garzon, Jessica, Lopes de Menezes, Daniel, Martin-Regueira, Patricia, Beach, C.L., Watts, Justin
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
DiNardo, Courtney D., Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Zeidan, Amer M., Bluemmert, Iryna, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, de Botton, Stephane
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
Jeyaraju, Danny V, Hayati, Sheida, Polonskaia, Ann, Alapa, Maryam, Ugidos, Manuel, Browne, Andrew, Risueño, Alberto, Hagner, Patrick, Gupta, Vikas, Talpaz, Moshe, Hernandez, Christopher, Chia, Vincent, Martin-Regueira, Patricia, Lopes de Menezes, Daniel, La Motte-Mohs, Ross, Suragani, Rajasekhar NVS, Gandhi, Anita K.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martínez-López, Joaquín, Mustjoki, Satu, Porkka, Kimmo, Klisovic, Rebecca B., Wolf, Dominik, Busque, Lambert, Hernández-Boluda, Juan Carlos, Swanink, Rene, Martin Regueira, Patricia, Lipton, Jeffrey H.
Published in Leukemia & lymphoma (03.07.2021)
Published in Leukemia & lymphoma (03.07.2021)
Get full text
Journal Article
Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
De Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Lowenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Dohner, Hartmut, Fathi, Amir Tahmasb, Dinardo, Courtney Denton, Martin Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., Hasan, Maroof
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern
Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Xiaoli, Liu, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael R., Martin Regueira, Patricia, Sy, Oumar, Gurnani, Renuka, Saglio, Giuseppe
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
DiNardo, Courtney D., de Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Löwenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Döhner, Hartmut, Fathi, Amir T., Martin-Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., Hasan, Maroof
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article
Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
DiNardo, Courtney D., de Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Löwenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Döhner, Hartmut, Fathi, Amir T., Martin-Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., Hasan, Maroof
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article